• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT beats The Street with Q1 sales, earnings

May 2, 2018 By Sarah Faulkner

Intersect ENTShares in Intersect ENT (NSDQ:XENT) held steady today after the medical device maker topped expectations on Wall Street with its first-quarter results.

The Menlo Park, Calif.-based company posted a net loss of -$6.1 million, or -21¢ per share, on sales of $24.7 million for the 3 months ended March 31, for bottom-line growth of 8.8% on sales growth of 20.8% compared with the same period last year.

Earnings per share were -21¢, ahead of consensus on The Street, where analysts were looking for sales of $23.6 million.

Intersect ENT said it expects to post sales of $111 million to $116 million for the full year. Second-quarter sales are pegged at $27.7 million to $28.2 million.

Last month, the company launched its steroid-releasing sinus implant, Sinuva, in the U.S. Intersect ENT’s drug-eluting device is designed to treat nasal polyp disease in patients who have previously undergone sinus surgery.

Management reportedly told analysts that initial feedback from physicians and patients has been positive. Users have specifically highlighted the device’s ease-of-use and the benefit of performing the procedure in a provider’s office, according to Leerink analysts  Richard Newitter, Jaime Morgan and Dylan Gantley.

The company’s Encore study, which is evaluating the repeat use of Sinuva, is slated to produce results in the second quarter of 2018, the analysts wrote in a note to investors.

XENT shares were trading at $40.30 apiece today in mid-morning activity, up 0.8%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS